Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. - Wikidata - wikimedia - TriplyDB

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

http://www.wikidata.org/entity/Q34181048

about

Prevention of vertical transmission of HIV-1 in resource-limited settings The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs Asking the right questions: developing evidence-based strategies for treating HIV in women and children Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges.Auditory Alterations in Children Infected by Human Immunodeficiency Virus Verified Through Auditory Processing Test Measuring infant memory: Utility of the visual paired-comparison test paradigm for studies in developmental neurotoxicology.Changes in Fertility at the Population Level in the Era of ART in Rural Malawi.Risk factors of HIV-1 vertical transmission (VT) and the influence of antiretroviral therapy (ART) in pregnancy outcome.HIV-exposed infants: rethinking care for a lifelong condition.Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs)Zidovudine exposure in HIV-1 infected Tanzanian women increases mitochondrial DNA levels in placenta and umbilical cords Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age.Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.Brain Imaging and Neurodevelopment in HIV-uninfected Thai Children Born to HIV-infected Mothers NeuroAIDS in Africa Reproductive health decision-making in perinatally HIV-infected adolescents and young adults Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.Family adversity and autonomic reactivity association with immune changes in HIV-affected school children.Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?Developmental delay and behavioral disorders in 59 HIV-exposed uninfected infants.Antiretroviral Treatment in HIV-1-Positive Mothers: Neurological Implications in Virus-Free Children Perinatally acquired HIV infection: long-term neuropsychological consequences and challenges ahead.Neurodevelopment of HIV-Exposed and HIV-Unexposed Uninfected Children at 24 Months.Longitudinal development of cognitive, visuomotor and adaptive behavior skills in HIV uninfected children, aged 3-5 years of age, exposed pre- and perinatally to anti-retroviral medications.Development assessment of HIV exposed children aged 6-18 months: a cohort study from North India.Neurodevelopmental outcome of HIV-exposed but uninfected infants in the Mother and Infants Health Study, Cape Town, South Africa.Quality of caregiving is positively associated with neurodevelopment during the first year of life among HIV-exposed uninfected children in Uganda.Neurodevelopment in Young Children Born to HIV-Infected Mothers: A Meta-analysis.Newborn hearing screening in infants born to HIV-seropositive mothers.In utero exposure to antiretrovirals and neurodevelopment among HIV-exposed uninfected children in Botswana.Perinatal HIV Infection or Exposure Is Associated With Low N-Acetylaspartate and Glutamate in Basal Ganglia at Age 9 but Not 7 Years.Trends in Neonatal Prophylaxis and Predictors of Combination Antiretroviral Prophylaxis in US Infants from 1990 to 2015

P2860

Q22241479-AB74EF82-617E-4161-92F6-ECF90E92485F Q26744617-CB10B7A9-F565-4A17-AC1F-7435C2BE3716 Q28743488-DA3AE044-690C-44D8-9106-73C235106A6C Q30244368-19AF0FFC-C7DD-4DB0-8FF6-88848415BC88 Q30366324-DCFC7C48-25F9-4E4D-9B96-697BCEB600B1 Q33645177-5DB97E6F-2113-48BC-9914-22D9B2591A48 Q33832976-E8FDCB93-33C0-4666-BBC3-3ADD9605F17E Q33859660-9FC968C0-E836-4203-ADF9-8A585AFD22BF Q33871174-BE63EF70-D86A-4F0A-9F3F-850B1C7F0A33 Q34005836-F400B320-CAE0-44CF-A75E-9759E6301975 Q34200645-6BF239CE-4B4A-4C40-B0F6-A44906A898FD Q34358732-D3677FBD-7694-4055-8263-0DBED9D10AA0 Q34440361-B1212B53-FBD4-44DB-A13A-98DAA3752451 Q35106962-00523AF0-B2F3-4C5C-85DA-8DA3569316C4 Q35924264-E94F96FE-3DD2-435D-9C59-547F698A63B2 Q36073155-EABD7B9F-1812-405B-B1AA-8877745F9E64 Q36547128-36A235CB-F554-4E47-A184-8A5C18262C95 Q36941958-7AECE31E-3117-43DA-B6CC-ED17FB2158B9 Q37045192-4FE78877-693F-46B4-83E2-1CB25EE3E35C Q37315334-B89A7F23-F116-47B8-82E2-7C9E45EB03D7 Q37342120-C891C133-CF69-4D43-B14C-E5603FE0EAE4 Q37597830-0A720150-A9DF-42A6-91C3-C85A8D4CEF52 Q37691000-0F0EE839-A521-48C7-ACE7-9B00F1C09482 Q38201765-2BFC2091-B833-4B34-A7E0-41D3D43DFD6F Q40040103-555E8A4B-3422-452B-B615-5EA29A18361B Q40221645-8E0A2C28-C0E5-485A-8F6A-51C5F3CAC7EA Q40300667-8B27B37E-3A48-4631-852F-11657023FAEB Q46868578-9E29A98D-D889-4604-9015-EF0358EAAEA8 Q47180418-0FE370E0-40D6-4E16-B181-BD57AC2AC69C Q49646980-9654D880-6676-465F-A408-FD62115104D0 Q50431918-2E18EBBE-3308-411D-A735-11F08E9D87CA Q51365493-4C35B0D9-8C57-4C66-8943-C2DEB261ABA0 Q55113867-C78FBA65-5EC6-40AB-91AB-98822F07B955 Q57826130-39207DD3-FDA0-4D73-B28B-4C5686D223C3

P2860

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

http://www.wikidata.org/entity/Q34181048

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@ast

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@en

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@nl

type

label

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@ast

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@en

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@nl

prefLabel

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@ast

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@en

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@nl

P1433

Q34181048-1F602C89-7976-410C-A7CC-1BC4DFCAD81C

P1476

Q34181048-0A1B7DBE-ACCA-4028-8BA9-0D2DCB307FBB

P2093

Q34181048-0A068DB5-7C43-41C6-88C3-B873D14D47C6

Q34181048-2E60A9AB-FA4D-482F-9A24-FF1158008BD6

Q34181048-582DD2CD-1868-4743-ACF6-5E3D796CF453

Q34181048-6FE7770B-0420-4397-AC73-E889498CD974

Q34181048-7828A1B7-7CB0-44E3-BEDE-9FBC07140C5C

P2860

Q34181048-17570033-4D83-4EF8-B26C-D8CF92296FA9

Q34181048-1B076FA2-A7BA-4DB7-9D34-64969C6F501D

Q34181048-226B78E6-FE06-4BEC-B936-8985FB47DE92

Q34181048-2866A105-61BB-4065-9328-4FB3A971C5D1

Q34181048-2D618AE2-81AC-4149-A878-8DB7DF9F2DB6

Q34181048-2E0C01DB-7E64-4446-8755-684CC505EBC3

Q34181048-310869EE-78DF-487A-A27A-6CD7FD61396B

Q34181048-32CC48E6-88B1-4B7B-9A66-F0776A682F85

Q34181048-37D05AA6-FA9A-4C87-A626-53BB1B5189D8

Q34181048-390FF00C-14BC-4806-8FC9-13BFB625976B

P304

Q34181048-FECF40EA-6737-460C-98A9-A48CEAC1B67A

P31

Q34181048-F4FEE03D-4178-479E-B202-70600B5F68D9

P356

Q34181048-1E83E7B4-FDAC-49D9-B74C-823330D519DA

P407

Q34181048-9E97D36C-F081-4D72-A3DE-D64A604E00A0

P433

Q34181048-C0A97AAA-F2AE-4EFB-88CC-68B88F4FC4C4

P478

Q34181048-570CA1C0-DD8A-4CFD-B819-F46DF925E2C5

P50

Q34181048-7FCBDBF7-E447-4B13-BFCA-66419023CD05

Q34181048-E9D6CBC2-A957-47ED-8144-C3FD34AD6F31

P577

Q34181048-F643A160-0559-4D5B-A2BA-D5426AD1E5F7

P5875

Q34181048-B2D76BE9-FC46-4C13-954C-2197EBDC800A

P698

Q34181048-FC7C29D7-D294-4156-B989-1A57D4252DB3

P921

Q34181048-B455D85C-8A4C-4906-B290-DEDB6C236F0D

P932

Q34181048-F0A8D3EA-43E4-420A-91D2-BC7B42ADD708

P356

P1433

P1476

Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.

@en

P2093

Kathleen Malee

http://www.w3.org/2001/XMLSchema#string

Michael D Hughes

http://www.w3.org/2001/XMLSchema#string

Miguel Marino

http://www.w3.org/2001/XMLSchema#string

PACTG 219C Team

http://www.w3.org/2001/XMLSchema#string

Paige L Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

Early cognitive and motor development among infants born to women infected with human immunodeficiency virus. Women and Infants Transmission Study Group.

Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study.

Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance.

Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA.

Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants.

Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.

P304

e250-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1542/PEDS.2009-1112

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41056159

http://www.w3.org/2001/XMLSchema#string

P698

20083530

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2951128

http://www.w3.org/2001/XMLSchema#string